The Combined Mutation Of Hbv T1763A1764 After 6-Month Interferon Treatment

Objective In order to observe the combined mutation of HBV T1762/A1764 in chronic hepatitis B patients after 6-month inter-feron treatment, and the response of HBV DNA quatility, HBV marker ,alanine aminotransferase transaminaeC ALT) ,aspar-tate aminotransferase (AST),serum total bilirubinCtBil).Method The mismatched PCR combined with a restriction tragment length polymorphism assay (PCR-RFLP) was used in this study. We compared the number of combined mutation of HBV T1762/A1764 in the 38-patient interferon treatment group and 30-patient nutrient treatment control group; 25 HBV T1762/A1764 combined mutation patients and 13 non-HBV T1762/A1764 combined mutation patients were chosen as mutation group and non-mutation group from 38 patients after 6 month interferon treatment , we compared the HBsAg, HBcAb, HBeAg in these patients; The above-mentioned two groups were compared HBV DNA quantification, ALT, AST, TBil separately with a control group of 22 patients who were treated with nutrients in 6 month.Result After 6 month,the number of A1762/T1764 conbined mutation in interferon group was more than the number in control group (P<0. 05); There were more HBeAg negative patients in mutation group than in non-mutation group(P<0. 05); After 6 month treatment the HBV DNA quantification, ALT, AST, TBil of above-mentioned two groups were seriously different with the 22- patient s-control-group ( P 0. 05).Conclusion The 6 month interferon treatment could result in HBV T1762/A1764 combined mutation which made HBeAg negtive; After 6-month-interferon-treatment the patients infected by HBV T1762/A1764 combined mutation couldn't aggravate hepato-cyte-injure.